Acute Lung Injury mouse model shows similar symptoms to COVID-19 patients
We would like to introduce the Liposaccharide-induced Acute Lung Injury model (LPS model) – an ARDS model that shows symptoms similar to that of COVID-19 patients.
It has been reported that COVID-19 patients develop symptoms of acute pneumonia and lung fibrosis. Acute pneumonia presents as an initial symptom of lung injury, and progresses to Acute Respiratory Distress Syndrome (ARDS). It has been confirmed that in ARDS, activated neutrophils damage the lung tissue, causing cell infiltration and edema (swelling).
The LPS model is a widely used model for ARDS.
SMC Laboratories’ LPS model shows similarities to acute pneumonia-derived ARDS, such as a significant increase in neutrophils as well as a rise in IL-6, so we believe it is an appropriate model for pharmacological evaluation of ARDS-targeting drug candidates.
We also offer the Bleomycin-induced lung fibrosis model, which many of our clients use to test the preventative/therapeutic efficacy of compounds against lung fibrosis observed in mid-late stage lung disease.
Through our LPS model and BLM-IPF model, we believe we can answer the needs of clients targeting both the early and mid-late stages of lung damage and COVID-19 symptoms.
Please see the attached document for further details of our LPS model.